Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

49 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Risk of secondary progressive multiple sclerosis: A longitudinal study.
Fambiatos A, Jokubaitis V, Horakova D, Kubala Havrdova E, Trojano M, Prat A, Girard M, Duquette P, Lugaresi A, Izquierdo G, Grand'Maison F, Grammond P, Sola P, Ferraro D, Alroughani R, Terzi M, Hupperts R, Boz C, Lechner-Scott J, Pucci E, Bergamaschi R, Van Pesch V, Ozakbas S, Granella F, Turkoglu R, Iuliano G, Spitaleri D, McCombe P, Solaro C, Slee M, Ampapa R, Soysal A, Petersen T, Sanchez-Menoyo JL, Verheul F, Prevost J, Sidhom Y, Van Wijmeersch B, Vucic S, Cristiano E, Saladino ML, Deri N, Barnett M, Olascoaga J, Moore F, Skibina O, Gray O, Fragoso Y, Yamout B, Shaw C, Singhal B, Shuey N, Hodgkinson S, Altintas A, Al-Harbi T, Csepany T, Taylor B, Hughes J, Jun JK, van der Walt A, Spelman T, Butzkueven H, Kalincik T. Fambiatos A, et al. Among authors: kubala havrdova e. Mult Scler. 2020 Jan;26(1):79-90. doi: 10.1177/1352458519868990. Epub 2019 Aug 9. Mult Scler. 2020. PMID: 31397221
Evolution of Brain Volume Loss Rates in Early Stages of Multiple Sclerosis.
Uher T, Krasensky J, Malpas C, Bergsland N, Dwyer MG, Kubala Havrdova E, Vaneckova M, Horakova D, Zivadinov R, Kalincik T. Uher T, et al. Among authors: kubala havrdova e. Neurol Neuroimmunol Neuroinflamm. 2021 Mar 16;8(3):e979. doi: 10.1212/NXI.0000000000000979. Print 2021 May. Neurol Neuroimmunol Neuroinflamm. 2021. PMID: 33727311 Free PMC article. Clinical Trial.
Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data.
Coles AJ, Jones JL, Vermersch P, Traboulsee A, Bass AD, Boster A, Chan A, Comi G, Fernández Ó, Giovannoni G, Kubala Havrdova E, LaGanke C, Montalban X, Oreja-Guevara C, Piehl F, Wiendl H, Ziemssen T. Coles AJ, et al. Among authors: kubala havrdova e. Mult Scler. 2022 Apr;28(5):842-846. doi: 10.1177/13524585211061335. Epub 2021 Dec 9. Mult Scler. 2022. PMID: 34882037 Free PMC article. Review.
Natalizumab Induces Changes of Cerebrospinal Fluid Measures in Multiple Sclerosis.
Ganapathy Subramanian R, Horakova D, Vaneckova M, Lorincz B, Krasensky J, Kubala Havrdova E, Uher T. Ganapathy Subramanian R, et al. Among authors: kubala havrdova e. Diagnostics (Basel). 2021 Nov 29;11(12):2230. doi: 10.3390/diagnostics11122230. Diagnostics (Basel). 2021. PMID: 34943468 Free PMC article.
Multiple Sclerosis and Microbiome.
Preiningerova JL, Jiraskova Zakostelska Z, Srinivasan A, Ticha V, Kovarova I, Kleinova P, Tlaskalova-Hogenova H, Kubala Havrdova E. Preiningerova JL, et al. Among authors: kubala havrdova e. Biomolecules. 2022 Mar 11;12(3):433. doi: 10.3390/biom12030433. Biomolecules. 2022. PMID: 35327624 Free PMC article. Review.
49 results